Merck Serono slips on 'currency headwinds'
This article was originally published in Scrip
Executive Summary
Merck KGaA's biopharmaceutical division, Merck Serono, saw total revenue decrease by 1.5% in the second quarter to €1.6bn compared with the same period last year. Merck said that "despite moderate organic growth" of 2%, reported sales declined by 1% overall to €1.5bn due to "currency headwinds" of -3%.